Business Context and Reporting Period
This Form 8-K is a current report filed by Millendo Therapeutics, Inc. (noted as Tempest Therapeutics in metadata) on March 29, 2019. The filing serves to announce the company's financial results for the fiscal year ended December 31, 2018, which were detailed in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only indicates that the results for the year ended December 31, 2018, have been announced.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information is furnished under Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as they are absent from this cover document.
- Confirm the company name discrepancy between the metadata ("Tempest Therapeutics") and the filing ("Millendo Therapeutics, Inc.").
- Note that this document is a notification of results rather than a detailed financial statement; full analysis requires the referenced press release.